Zai Lab

再鼎医药今日放量上涨 11.7%，因 Q2 营收超预期至 1.063 亿美元且花旗将目标价从 37 美元上调至 45 美元。盘前交易于 21.5-22 美元区间平稳，开盘后迅速拉升，盘中最高触及 23.98 美元，最终收于 23.32 美元，全天成交 204.6 万股，为近半年日均量的 2 倍以上。公司正加速商业化，TIVDAK 获中国 NMPA 批准用于宫颈癌，DLL3 靶向 ADC 获 FDA 孤儿药资格。不过每股亏损扩大至 0.5 美元，净亏损同比增 25%，基本面改善仍需时间验证。当前股价距 52 周高点 36.77 美元仍有 36.6% 空间，但已站上 MA20（19.6 美元）和 MA60（18.81 美元），YTD 涨幅达 34.6%。

Zai Lab (ZLAB.US) rose 5.2% during regular trading to $19.33, driven by better-than-expected Q2 revenue and pipeline progress. An 8-K filing revealed Q2 FY2026 revenue of $106.31 million, beating estimates, while the U.S. FDA granted Orphan Drug Designation to its DLL3-targeting ADC Zocilurtatug Pelitecan for neuroendocrine carcinomas. UBS maintains a Buy rating. The stock remains 50.84% below its 52-week high of $39.32, but has gained 11.54% YTD and sits above the MA60 ($18.72), though still slightly below the MA20 ($19.38), reflecting near-term momentum against long-term resistance.

Zai Lab opened lower and quickly extended losses, hitting an intraday low of $19.56, down over 5% from its pre-market high of $20.75, before closing at $19.61. The pressure was largely driven by insider selling signals: director William Lis disposed of 7,040 shares for ~$127,000 on July 10, while director Richard Gaynor purchased 1,736 shares on July 5, creating directional divergence. Separately, the company disclosed grants of 178,968 restricted shares to all directors and issued ~3.7 million new shares under equity incentive plans, raising dilution concerns. On the positive side, TIVDAK recently received China NMPA approval for recurrent or metastatic cervical cancer, adding pipeline momentum; analysts raised the 12-month price target to $32.86, implying roughly 78% upside. The stock currently trades below both its MA20 ($19.21) and MA60 ($19.21), with a YTD gain of 13.16% and a 52.4% discount from the 52-week high of $41.20.

ZLAB closed sharply higher at $20.345, up 5.41% from the prior close, driven by the ongoing positive sentiment following China's NMPA approval of TIVDAK for recurrent or metastatic cervical cancer. The stock rallied to an intraday high of $20.680, recovering over 8% from its pre-market low of $19.150. Despite a 6.46% YoY decline in Q1 revenue to $99.6 million and a widened net loss of $51.0 million, the pipeline's value proposition attracted a price target raise to $32.86 by an analyst. However, the stock still trades below its 52-week high, and recent insider selling adds a note of caution.